Eintrag weiter verarbeiten
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma
Gespeichert in:
| Zeitschriftentitel: | Blood |
|---|---|
| Personen und Körperschaften: | , , , , , , , |
| In: | Blood, 104, 2004, 8, S. 2269-2271 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Hematology
|
| Schlagwörter: |
| author_facet |
Kaufmann, Hannes Raderer, Markus Wöhrer, Stefan Püspök, Andreas Bankier, Alexander Zielinski, Christoph Chott, Andreas Drach, Johannes Kaufmann, Hannes Raderer, Markus Wöhrer, Stefan Püspök, Andreas Bankier, Alexander Zielinski, Christoph Chott, Andreas Drach, Johannes |
|---|---|
| author |
Kaufmann, Hannes Raderer, Markus Wöhrer, Stefan Püspök, Andreas Bankier, Alexander Zielinski, Christoph Chott, Andreas Drach, Johannes |
| spellingShingle |
Kaufmann, Hannes Raderer, Markus Wöhrer, Stefan Püspök, Andreas Bankier, Alexander Zielinski, Christoph Chott, Andreas Drach, Johannes Blood Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma Cell Biology Hematology Immunology Biochemistry |
| author_sort |
kaufmann, hannes |
| spelling |
Kaufmann, Hannes Raderer, Markus Wöhrer, Stefan Püspök, Andreas Bankier, Alexander Zielinski, Christoph Chott, Andreas Drach, Johannes 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood-2004-03-1091 <jats:title>Abstract</jats:title><jats:p>We evaluated a treatment strategy targeting both lymphoma cells (by rituximab) and the microenvironment (by thalidomide) in 16 patients with relapsed/refractory mantle cell lymphoma (MCL). Rituximab was administered at 375 mg/m2 for 4 weekly doses concomitantly with thalidomide (200 mg daily, with a dose increment to 400 mg on day 15), which was continued as maintenance therapy until progression/relapse. Thirteen patients (81%) experienced an objective response, with 5 complete responders (31%). Median progression-free survival (PFS) was 20.4 months (95% confidence interval [CI], 17.3-23.6 months), and estimated 3-year survival was 75%. In patients achieving a complete response, PFS after rituximab plus thalidomide was longer than PFS after the preceding chemotherapy. Severe adverse events included 2 thromboembolic events and 1 grade IV neutropenia associated with thalidomide. Our results suggest that rituximab plus thalidomide has marked antitumor activity in relapsed/refractory MCL and a low toxicity profile, which warrants further evaluation in MCL.</jats:p> Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma Blood |
| doi_str_mv |
10.1182/blood-2004-03-1091 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin Chemie und Pharmazie Biologie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDA0LTAzLTEwOTE |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDA0LTAzLTEwOTE |
| institution |
DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 |
| imprint |
American Society of Hematology, 2004 |
| imprint_str_mv |
American Society of Hematology, 2004 |
| issn |
0006-4971 1528-0020 |
| issn_str_mv |
0006-4971 1528-0020 |
| language |
English |
| mega_collection |
American Society of Hematology (CrossRef) |
| match_str |
kaufmann2004antitumoractivityofrituximabplusthalidomideinpatientswithrelapsedrefractorymantlecelllymphoma |
| publishDateSort |
2004 |
| publisher |
American Society of Hematology |
| recordtype |
ai |
| record_format |
ai |
| series |
Blood |
| source_id |
49 |
| title |
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma |
| title_unstemmed |
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma |
| title_full |
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma |
| title_fullStr |
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma |
| title_full_unstemmed |
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma |
| title_short |
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma |
| title_sort |
antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma |
| topic |
Cell Biology Hematology Immunology Biochemistry |
| url |
http://dx.doi.org/10.1182/blood-2004-03-1091 |
| publishDate |
2004 |
| physical |
2269-2271 |
| description |
<jats:title>Abstract</jats:title><jats:p>We evaluated a treatment strategy targeting both lymphoma cells (by rituximab) and the microenvironment (by thalidomide) in 16 patients with relapsed/refractory mantle cell lymphoma (MCL). Rituximab was administered at 375 mg/m2 for 4 weekly doses concomitantly with thalidomide (200 mg daily, with a dose increment to 400 mg on day 15), which was continued as maintenance therapy until progression/relapse. Thirteen patients (81%) experienced an objective response, with 5 complete responders (31%). Median progression-free survival (PFS) was 20.4 months (95% confidence interval [CI], 17.3-23.6 months), and estimated 3-year survival was 75%. In patients achieving a complete response, PFS after rituximab plus thalidomide was longer than PFS after the preceding chemotherapy. Severe adverse events included 2 thromboembolic events and 1 grade IV neutropenia associated with thalidomide. Our results suggest that rituximab plus thalidomide has marked antitumor activity in relapsed/refractory MCL and a low toxicity profile, which warrants further evaluation in MCL.</jats:p> |
| container_issue |
8 |
| container_start_page |
2269 |
| container_title |
Blood |
| container_volume |
104 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792343281778032641 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T16:49:12.49Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Antitumor+activity+of+rituximab+plus+thalidomide+in+patients+with+relapsed%2Frefractory+mantle+cell+lymphoma&rft.date=2004-10-15&genre=article&issn=1528-0020&volume=104&issue=8&spage=2269&epage=2271&pages=2269-2271&jtitle=Blood&atitle=Antitumor+activity+of+rituximab+plus+thalidomide+in+patients+with+relapsed%2Frefractory+mantle+cell+lymphoma&aulast=Drach&aufirst=Johannes&rft_id=info%3Adoi%2F10.1182%2Fblood-2004-03-1091&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792343281778032641 |
| author | Kaufmann, Hannes, Raderer, Markus, Wöhrer, Stefan, Püspök, Andreas, Bankier, Alexander, Zielinski, Christoph, Chott, Andreas, Drach, Johannes |
| author_facet | Kaufmann, Hannes, Raderer, Markus, Wöhrer, Stefan, Püspök, Andreas, Bankier, Alexander, Zielinski, Christoph, Chott, Andreas, Drach, Johannes, Kaufmann, Hannes, Raderer, Markus, Wöhrer, Stefan, Püspök, Andreas, Bankier, Alexander, Zielinski, Christoph, Chott, Andreas, Drach, Johannes |
| author_sort | kaufmann, hannes |
| container_issue | 8 |
| container_start_page | 2269 |
| container_title | Blood |
| container_volume | 104 |
| description | <jats:title>Abstract</jats:title><jats:p>We evaluated a treatment strategy targeting both lymphoma cells (by rituximab) and the microenvironment (by thalidomide) in 16 patients with relapsed/refractory mantle cell lymphoma (MCL). Rituximab was administered at 375 mg/m2 for 4 weekly doses concomitantly with thalidomide (200 mg daily, with a dose increment to 400 mg on day 15), which was continued as maintenance therapy until progression/relapse. Thirteen patients (81%) experienced an objective response, with 5 complete responders (31%). Median progression-free survival (PFS) was 20.4 months (95% confidence interval [CI], 17.3-23.6 months), and estimated 3-year survival was 75%. In patients achieving a complete response, PFS after rituximab plus thalidomide was longer than PFS after the preceding chemotherapy. Severe adverse events included 2 thromboembolic events and 1 grade IV neutropenia associated with thalidomide. Our results suggest that rituximab plus thalidomide has marked antitumor activity in relapsed/refractory MCL and a low toxicity profile, which warrants further evaluation in MCL.</jats:p> |
| doi_str_mv | 10.1182/blood-2004-03-1091 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin, Chemie und Pharmazie, Biologie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDA0LTAzLTEwOTE |
| imprint | American Society of Hematology, 2004 |
| imprint_str_mv | American Society of Hematology, 2004 |
| institution | DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161 |
| issn | 0006-4971, 1528-0020 |
| issn_str_mv | 0006-4971, 1528-0020 |
| language | English |
| last_indexed | 2024-03-01T16:49:12.49Z |
| match_str | kaufmann2004antitumoractivityofrituximabplusthalidomideinpatientswithrelapsedrefractorymantlecelllymphoma |
| mega_collection | American Society of Hematology (CrossRef) |
| physical | 2269-2271 |
| publishDate | 2004 |
| publishDateSort | 2004 |
| publisher | American Society of Hematology |
| record_format | ai |
| recordtype | ai |
| series | Blood |
| source_id | 49 |
| spelling | Kaufmann, Hannes Raderer, Markus Wöhrer, Stefan Püspök, Andreas Bankier, Alexander Zielinski, Christoph Chott, Andreas Drach, Johannes 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood-2004-03-1091 <jats:title>Abstract</jats:title><jats:p>We evaluated a treatment strategy targeting both lymphoma cells (by rituximab) and the microenvironment (by thalidomide) in 16 patients with relapsed/refractory mantle cell lymphoma (MCL). Rituximab was administered at 375 mg/m2 for 4 weekly doses concomitantly with thalidomide (200 mg daily, with a dose increment to 400 mg on day 15), which was continued as maintenance therapy until progression/relapse. Thirteen patients (81%) experienced an objective response, with 5 complete responders (31%). Median progression-free survival (PFS) was 20.4 months (95% confidence interval [CI], 17.3-23.6 months), and estimated 3-year survival was 75%. In patients achieving a complete response, PFS after rituximab plus thalidomide was longer than PFS after the preceding chemotherapy. Severe adverse events included 2 thromboembolic events and 1 grade IV neutropenia associated with thalidomide. Our results suggest that rituximab plus thalidomide has marked antitumor activity in relapsed/refractory MCL and a low toxicity profile, which warrants further evaluation in MCL.</jats:p> Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma Blood |
| spellingShingle | Kaufmann, Hannes, Raderer, Markus, Wöhrer, Stefan, Püspök, Andreas, Bankier, Alexander, Zielinski, Christoph, Chott, Andreas, Drach, Johannes, Blood, Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma, Cell Biology, Hematology, Immunology, Biochemistry |
| title | Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma |
| title_full | Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma |
| title_fullStr | Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma |
| title_full_unstemmed | Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma |
| title_short | Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma |
| title_sort | antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma |
| title_unstemmed | Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma |
| topic | Cell Biology, Hematology, Immunology, Biochemistry |
| url | http://dx.doi.org/10.1182/blood-2004-03-1091 |